Jason Zemansky
Stock Analyst at B of A Securities
(4.88)
# 62
Out of 5,182 analysts
55
Total ratings
76.92%
Success rate
40.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $8 → $9 | $3.43 | +162.39% | 6 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Buy | $211 → $213 | $134.94 | +57.85% | 12 | Mar 24, 2026 | |
| LGND Ligand Pharmaceuticals | Initiates: Buy | $244 | $232.32 | +5.03% | 1 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Buy | $34 | $8.56 | +297.20% | 1 | Mar 2, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $1.88 | +219.15% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $11.37 | +67.11% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $24.80 | +4.84% | 6 | Nov 28, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.74 | +845.95% | 6 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $60.69 | -7.73% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $40.89 | -24.19% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $29 | $8.83 | +228.43% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $31 | $21.11 | +46.85% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $1.91 | +30.89% | 5 | Jun 20, 2024 |
Rocket Pharmaceuticals
Mar 30, 2026
Maintains: Buy
Price Target: $8 → $9
Current: $3.43
Upside: +162.39%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $211 → $213
Current: $134.94
Upside: +57.85%
Ligand Pharmaceuticals
Mar 11, 2026
Initiates: Buy
Price Target: $244
Current: $232.32
Upside: +5.03%
Eikon Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $34
Current: $8.56
Upside: +297.20%
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $1.88
Upside: +219.15%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $11.37
Upside: +67.11%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $24.80
Upside: +4.84%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.74
Upside: +845.95%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $60.69
Upside: -7.73%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $40.89
Upside: -24.19%
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.83
Upside: +228.43%
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $21.11
Upside: +46.85%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $1.91
Upside: +30.89%